{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:43:25Z","timestamp":1790203405252,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.revmed.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T17:46:42Z","timestamp":1409939202000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Amylose AL"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Jaccard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Desport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2014.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minesota, 1950\u00a0through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ddmec.2004.11.008","article-title":"Immune mechanisms of AL amyloidosis","volume":"1","author":"Perfetti","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.revmed.2014.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.08.003_bib0020","first-page":"1","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared to monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"10","author":"Bochtler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0025","first-page":"94","article-title":"Detection of monoclonal free light chains by nephelometry in systemic AL amyloidosis","volume":"117","author":"Lachmann","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1006\/jmbi.2000.3908","article-title":"The protofilament substructure of amyloid fibrils","volume":"300","author":"Serpell","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/jmbi.1997.1348","article-title":"Common core structure of amyloid fibrils by synchrotron X-ray diffraction","volume":"273","author":"Sunde","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.revmed.2006.06.013","article-title":"Traitement de l\u2019amylose AL. Donn\u00e9es actuelles","volume":"27","author":"Jaccard","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.08.003_bib0045","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0050","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2014.08.003_bib0060","first-page":"371","article-title":"Nephropathie amyloide AL\u00a0: donn\u00e9es cliniques, \u00e9pid\u00e9miologiques et pronostiques d\u2019une s\u00e9rie de 41\u00a0patients","volume":"5","author":"Moumas","year":"2009","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.revmed.2014.08.003_bib0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322\u00a0April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0070","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis support of patients with primary systemic amyloidosis. A study of 211\u00a0patients","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2014.08.003_bib0075","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2214\/ajr.129.5.851","article-title":"Radiological findings in renal amyloidosis","volume":"129","author":"Ekelund","year":"1977","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.revmed.2013.05.003","article-title":"[Cardiac amyloidosis: a case series of 14\u00a0patients, description and prognosis]","volume":"34","author":"Isabel","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.08.003_bib0085","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.acvd.2011.10.004","article-title":"Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis","volume":"104","author":"Mohty","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.revmed.2014.08.003_bib0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3,3- diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.revmed.2014.08.003_bib0095","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0105","first-page":"110","article-title":"Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment","volume":"81","author":"Marinone","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2014.08.003_bib0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/13506129.2010.543443","article-title":"Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool","volume":"18","author":"Loustaud-Ratti","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2014.08.003_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MD.0b13e31816c43b6","article-title":"The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72\u00a0patients","volume":"87","author":"Terrier","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2014.08.003_bib0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","article-title":"Amyloidosis: review of 236\u00a0cases","volume":"54","author":"Kyle","year":"1975","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2014.08.003_bib0125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2014.08.003_bib0130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1538-7836.2007.02457.x","article-title":"Increased plasmin-a2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses","volume":"5","author":"Bouma","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2014.08.003_bib0135","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0140","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.4065\/75.12.1264","article-title":"Primary localized amyloidosis of the urinary bladder: a case series of 31\u00a0patients","volume":"75","author":"Tirzaman","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2014.08.003_bib0145","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archinte.1983.00350080055015","article-title":"Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis","volume":"143","author":"Libbey","year":"1983","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2014.08.003_bib0150","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/dc.10370","article-title":"Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinical useful test?","volume":"30","author":"Ansari-Lari","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0155","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jms.3264","article-title":"Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis","volume":"48","author":"Theis","year":"2013","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.revmed.2014.08.003_bib0160","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.revmed.2014.08.003_bib0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CLM.2009.n.020","article-title":"Transplantation for IgM amyloidosis and IgM myeloma","volume":"9","author":"Gertz","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2014.08.003_bib0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/13506129.2011.574354054","article-title":"Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex","volume":"18","author":"Penot","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2014.08.003_bib0180","article-title":"Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity","volume":"114","author":"Zonder","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.revmed.2014.08.003_bib0185","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0190","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0195","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light chain amyloidosis: long-term results from a phase 2\u00a0trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0200","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2014.08.003_bib0205","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2014.08.003_bib0210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2014.08.003_bib0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2014.08.003_bib0220","first-page":"3831S","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866314006195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866314006195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:34:13Z","timestamp":1759336453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866314006195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0248866314006195"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2014.08.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amylose AL","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}